NEW YORK – In a document filed with the US Securities and Exchange Commission on Thursday, Abbott Laboratories said it had entered a five-year, $5 billion revolving credit agreement with JP Morgan Chase as the administrative agent.
Under the agreement, Abbott can borrow up to $5 billion on an unsecured basis and any borrowings will mature and be payable five years from the effective date, Nov. 12, 2020. The borrowings will bear interest based on either a base rate or a Eurodollar rate, the filing said.